Microba Life Sciences' (ASX:MAP) Q3 FY24 revenue hits $4M

Microba Life Sciences reported unaudited revenue of $4 million in the third quarter of FY24, up 82% quarter over quarter and 297% year over year.

The personal testing and supplements segment was notable, which grew 110% quarterly and 420% yearly, generating $3.2 million.

The launch of MetaPanel, a pathogen test with Sonic Healthcare (ASX:SHL), marked Microba's entry into medical diagnostics, with initial sales across Australia.

Revenue from the UK acquisition of Invivo Clinical contributed $2.2 million, meeting expectations.